Vogelxo Patent Expiration

Vogelxo is a drug owned by Upsher Smith Laboratories Llc. It is protected by 4 US drug patents filed from 2014 to 2017 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 11, 2034. Details of Vogelxo's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9622340 Flexible circuit board and method for manufacturing same
Feb, 2034

(9 years from now)

Active
US8785426 Testosterone gel compositions and related methods
Feb, 2034

(9 years from now)

Active
US9662340 Testosterone gel compositions and related methods
Feb, 2034

(9 years from now)

Active
US9295675 Testosterone gel compositions and related methods
Feb, 2034

(9 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vogelxo's patents.

Given below is the list of recent legal activities going on the following patents of Vogelxo.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 12 Jun, 2024 US9662340
Payment of Maintenance Fee, 8th Year, Large Entity 19 Aug, 2021 US8785426
Payment of Maintenance Fee, 4th Year, Large Entity 15 Sep, 2020 US9622340
Payment of Maintenance Fee, 4th Year, Large Entity 04 Jun, 2020 US9662340
Payment of Maintenance Fee, 4th Year, Large Entity 12 Oct, 2017 US8785426
Patent Issue Date Used in PTA Calculation 30 May, 2017 US9662340
Recordation of Patent Grant Mailed 30 May, 2017 US9662340
Email Notification 11 May, 2017 US9662340
Issue Notification Mailed 10 May, 2017 US9662340
Dispatch to FDC 03 May, 2017 US9662340


FDA has granted several exclusivities to Vogelxo. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Vogelxo, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Vogelxo.

Exclusivity Information

Vogelxo holds 1 exclusivities. All of its exclusivities have expired in 2017. Details of Vogelxo's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 04, 2017

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Vogelxo is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vogelxo's family patents as well as insights into ongoing legal events on those patents.

Vogelxo's Family Patents

Vogelxo has patent protection in a total of 7 countries. It's US patent count contributes only to 45.5% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Vogelxo.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Vogelxo's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 11, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Vogelxo Generic API suppliers:

Testosterone is the generic name for the brand Vogelxo. 15 different companies have already filed for the generic of Vogelxo, with Actavis Labs Ut Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Vogelxo's generic

Alternative Brands for Vogelxo

Vogelxo which is used for delivering testosterone through the skin., has several other brand drugs using the same active ingredient (Testosterone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Acerus
Natesto
Alza
Testoderm
Testoderm Tts
Antares Pharma Inc
Xyosted (autoinjector)
Auxilium Pharms Llc
Striant
Azurity
Testosterone Cypionate
Besins Hlthcare
Androgel
Eli Lilly And Co
Axiron
Endo Operations
Aveed
Fortesta
Testim
Marius Pharms Llc
Kyzatrex
Tolmar
Jatenzo
Verity
Tlando


Apart from brand drugs containing the same ingredient, some generics have also been filed for Testosterone, Vogelxo's active ingredient. Check the complete list of approved generic manufacturers for Vogelxo





About Vogelxo

Vogelxo is a drug owned by Upsher Smith Laboratories Llc. It is used for delivering testosterone through the skin. Vogelxo uses Testosterone as an active ingredient. Vogelxo was launched by Upsher Smith Labs in 2014.

Approval Date:

Vogelxo was approved by FDA for market use on 04 June, 2014.

Active Ingredient:

Vogelxo uses Testosterone as the active ingredient. Check out other Drugs and Companies using Testosterone ingredient

Treatment:

Vogelxo is used for delivering testosterone through the skin.

Dosage:

Vogelxo is available in the following dosage forms - gel, metered form for transdermal use, gel form for transdermal use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
12.5MG/1.25GM ACTUATION GEL, METERED Prescription TRANSDERMAL
50MG/5GM PACKET GEL Prescription TRANSDERMAL